| Balance Sheets | 2025-06-30 | |||
|---|---|---|---|---|
| Property and equipment, net | 89 | |||
| Patent and trademark rights, net | 2,168 | |||
| Prepaid expenses and other current assets | 190 | |||
| Marketable investments | 359 | |||
| Cash and cash equivalents | 476 | |||
| Total current assets | 1,025 | |||
| Other assets | 351 | |||
| Right of use asset, net | 496 | |||
| Total assets | 4,129 | |||
| Accrued expenses | 573 | |||
| Current portion of operating lease liability | 233 | |||
| Current portion of note payable, net | 2,290 | |||
| Accounts payable | 7,297 | |||
| Total current liabilities | 10,393 | |||
| Operating lease liability | 282 | |||
| Total liabilities | 10,675 | |||
| Accumulated deficit | -433,327 | |||
| Preferred stock, value-Series BConvertible Preferred Stock | 0 | |||
| Preferred stock, value-Series AJunior Participating Preferred Stock | 0 | |||
| Common stock, 0.001 par value, authorized shares - 350,000,000 issued and outstanding shares 764,188 and 655,263 as of june 30, 2025 and december 31, 2024, respectively | 1 | |||
| Additional paid-in capital | 426,780 | |||
| Total stockholders deficit | -6,546 | |||
| Total liabilities and stockholders deficit | 4,129 | |||
AIM ImmunoTech Inc. (AIMI)
AIM ImmunoTech Inc. (AIMI)